Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

Abstract Background Vedolizumab is safe and effective in adult patients with Crohn’s disease (CD) and ulcerative colitis (UC); however, data in children with inflammatory bowel disease (IBD) are scarce. Therefore, we evaluated vedolizumab use in a cohort of Austrian paediatric patients with IBD. Met...

Full description

Bibliographic Details
Main Authors: Anna-Maria Schneider, Daniel Weghuber, Benjamin Hetzer, Andreas Entenmann, Thomas Müller, Georg Zimmermann, Sebastian Schütz, Wolf-Dietrich Huber, Judith Pichler
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Gastroenterology
Subjects:
Crohn’s disease
Ulcerative colitis
Paediatrics
Integrin antagonist
Online Access:http://link.springer.com/article/10.1186/s12876-018-0868-x

Internet

http://link.springer.com/article/10.1186/s12876-018-0868-x

Similar Items